Details of the Drug Excipient
General Information of Drug Inactive Ingredient (DIG) (ID: E00112)
| DIG Name |
Arginine
|
||||
|---|---|---|---|---|---|
| Synonyms |
L-arginine; arginine; 74-79-3; L-(+)-Arginine; L(+)-Arginine; L-Arg; H-Arg-OH; (S)-2-Amino-5-guanidinopentanoic acid; (L)-Arginine; Arginina; ARGININE, L-; Arginine (VAN); L-Arginin; Argininum [INN-Latin]; Arginina [INN-Spanish]; L-Ornithine, N5-(aminoiminomethyl)-; Argamine; Argivene; Detoxargin; Levargin; L-alpha-Amino-delta-guanidinovaleric acid; Minophagen A; 1-Amino-4-guanidovaleric acid; CCRIS 3609; NSC 206269; arg; HSDB 1429; AI3-24165; UNII-94ZLA3W45F; MFCD00002635; (S)-2-Amino-5-guanidinovaleric acid; BRN 1725413; CHEBI:16467; (S)-2-Amino-5-((aminoiminomethyl)amino)pentanoic acid; L-Norvaline, 5-((aminoiminomethyl)amino)-; (S)-(+)-arginine; L-Arginine, monohydrochloride; 2-amino-5-guanidinovaleric acid; CHEMBL1485; (2S)-2-amino-5-guanidinopentanoic acid; (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; 94ZLA3W45F; Pentanoic acid, 2-amino-5-((aminoiminomethyl)amino)-, (S)-; (2S)-2-amino-5-(carbamimidamido)pentanoic acid; L-2-Amino-5-guanidinopentanoic acid; Arginine (L-Arginine); R-Gene; L-Norvaline, 5-[(aminoiminomethyl)amino]-; (2S)-2-amino-5-carbamimidamidopentanoic acid; DSSTox_CID_21056; DSSTox_RID_79618; Poly(L-arginine); DSSTox_GSID_41056; L(+)-Arginine, 98+%; C6H14N4O2; Argininum; Pentanoic acid, 2-amino-5-[(aminoiminomethyl)amino]-, (S)-; L-Arginine, homopolymer; Arginine [USAN:INN]; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid; CAS-74-79-3; Arginine [USP:INN]; EINECS 200-811-1; 2-AMINO-5-GUANIDINO-PENTANOIC ACID; (2S)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid; NSC203450; 3h-l-arginine; L-Arginine, labeled with tritium; 1laf; NSC-206269; L-a-Amino-d-guanidinovaleric acid; NCGC00015064-02; (S)-Arginine; L(+) arginine; L-Aryginine,(S); H-Arg; L-(+) arginine; L(+)-Arginine;; PubChem7933; L-Arginine (9CI); Arginine (USP/INN); Tocris-0663; (2S)-2-amino-5-guanidino-pentanoic acid; L-Arginine (JP17); GND; Lopac-A-5006; Arginine, L- (8CI); bmse000029; bmse000899; bmse000919; Epitope ID:140084; L-Arginine (H-Arg-OH); EC 200-811-1; SCHEMBL1791; 2-amino-5-guanidinovalerate; Lopac0_000077; Arginine hydrochloride(USAN); GTPL721; 4-04-00-02648 (Beilstein Handbook Reference); L-a-Amino-d-guanidinovalerate; L-Amino-4-guanidovaleric acid; US9138393, L-Arginine; US9144538, L-Arginine; 1-Amino-4-guanidovalerlic acid; DTXSID6041056; BDBM21959; L-Arginine, 99%, FCC, FG; BDBM181132; HMS3260O15; N5-(aminoiminomethyl)-L-Ornithine; HY-N0455; ZINC1532525; L-Arginine, Vetec(TM), 98.5%; Tox21_113046; Tox21_500077; AC-083; ANW-36527; L-alpha-Amino-delta-guanidinovalerate; L-Arginine, reagent grade, >=98%; s5634; AKOS006239069; AKOS015854096; Tox21_113046_1; AM81500; CCG-204172; DB00125; LP00077; MCULE-5108123240; SDCCGSBI-0050065.P002; L-Arginine, 99%, natural, FCC, FG; (s)-2-amino-5-guanidino-pentanoic acid; 5-[(aminoiminomethyl)amino]-L-Norvaline; NCGC00015064-01; NCGC00024715-01; NCGC00024715-02; NCGC00024715-03; NCGC00024715-04; NCGC00024715-05; NCGC00024715-10; NCGC00260762-01; 25212-18-4; 4455-52-1; AK-81231; AS-14190; K277; L-Arginine, BioUltra, >=99.5% (NT); SBI-0207062.P001; AB0014136; A0526; A7079; EU-0100077; L-Arginine, SAJ special grade, >=98.0%; A 5006; C00062; D02982; L-Arginine, Vetec(TM) reagent grade, >=98%; M02981; Y-8965; 14932-EP2316830A2; AB00374192_03; Norvaline, 5-[(aminoiminomethyl)amino]-, (L)-; 002A635; A837397; Q173670; SR-01000075479; SR-01000597671; (S)-2-amino-5-[(aminoiminomethyl)amino]-Pentanoate; (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate; SR-01000075479-1; SR-01000597671-1; W-104410; (S)-2-amino-5-[(aminoiminomethyl)amino]-Pentanoic acid; Arginine, European Pharmacopoeia (EP) Reference Standard; (2S)-2-amino-5-[(diaminomethylidene)amino]pentanoic acid; 7F15B0C7-356D-45D7-AC33-03AEE4394A0E; S-(+)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; UNII-0O72R8RF8A component ODKSFYDXXFIFQN-BYPYZUCNSA-N; UNII-FL26NTK3EP component ODKSFYDXXFIFQN-BYPYZUCNSA-N; L-Arginine, United States Pharmacopeia (USP) Reference Standard; L-Arginine, Pharmaceutical Secondary Standard; Certified Reference Material; L-; L-Arginine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%; L-Arginine, PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture
|
||||
| DIG Function |
Buffering agent; Dispersing agent
|
||||
| Formula |
C6H14N4O2
|
||||
| Canonical SMILES |
C(C[C@@H](C(=O)O)N)CN=C(N)N
|
||||
| InChI |
1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1
|
||||
| InChIKey |
ODKSFYDXXFIFQN-BYPYZUCNSA-N
|
||||
| Physicochemical Properties | Molecular Weight | 174.2 | Topological Polar Surface Area | 128 | |
| XlogP | -4.2 | Complexity | 176 | ||
| Heavy Atom Count | 12 | Rotatable Bond Count | 5 | ||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 4 | ||
Full List of Drug(s) Co-administrated with This DIG